A Randomized, Double-Blind, Phase 3 Trial of STA-4783 in Combination With Paclitaxel Versus Paclitaxel Alone for Treatment of Chemotherapy-Naive Subjects With Stage IV Metastatic Melanoma (SYMMETRY)

Trial Profile

A Randomized, Double-Blind, Phase 3 Trial of STA-4783 in Combination With Paclitaxel Versus Paclitaxel Alone for Treatment of Chemotherapy-Naive Subjects With Stage IV Metastatic Melanoma (SYMMETRY)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2014

At a glance

  • Drugs Elesclomol (Primary) ; Paclitaxel
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms SYMMETRY
  • Sponsors Synta Pharmaceuticals
  • Most Recent Events

    • 04 Jul 2012 Additional trial location (Spain) added as reported by European Clinical Trials Database record.
    • 06 Jun 2010 One-year overall survival results have been presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).
    • 05 Jun 2009 Interim results presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top